SEC Comment Letter 0000000000-24-007577 to Ginkgo Bioworks Holdings, Inc. (DNA)

Ginkgo Bioworks Holdings, Inc.
Date: July 3, 2024 · CIK: 0001830214 · Accession: 0000000000-24-007577

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-40097

Date

July 3, 2024

Author

Mark Dmytruk

Form

UPLOAD

Company

Ginkgo Bioworks Holdings, Inc.

Letter

July 3, 2024 Mark Dmytruk Chief Financial Officer Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue 8th Floor Boston, MA 02210 Re:Ginkgo Bioworks Holdings, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-40097 Dear Mark Dmytruk: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

July 3, 2024
Mark Dmytruk
Chief Financial Officer
Ginkgo Bioworks Holdings, Inc.
27 Drydock Avenue
8th Floor
Boston, MA 02210
Re:Ginkgo Bioworks Holdings, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-40097
Dear Mark Dmytruk:
            We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io